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Introduction
Prostaglanding E2 (PGE2) is an important mediator
of inflammatory pain and fever [1–3].It is synthesized
by two cyclooxygenase (COX)-isoforms, COX-1 and
COX-2, through conversion of arachidonic acid to the
intermediate PGH2 [4] which is subsequently isomer-
ized by three specific terminal PGE2-synthases to
PGE2. Due to its preferential coupling with COX-2,
selective inhibition of the microsomal PGE-synthase-1
(mPGES-1) is regarded as a promising new target in 
order to a more selective suppression of the PGE2
production during inflammation and nociceptive pro-
cessing [4]. Accordingly, several studies employing
mPGES-1-deficient mice demonstrated a major role
of mPGES-1 in PGE2-dependent processes such as
the inflammatory response to lipopolysaccharide
(LPS) [5], models of arthritis [3, 5], and immune-
induced pyresis [1] whereas its role in nociceptive
processing has not been studied in detail.
The endoperoxide intermediate PGH2 serves as a
common substrate for several prostaglandin synthas-
es. Therefore the fate of PGH2 in the absence of
mPGES-1 is of great importance for the evaluation of
the effects of mPGES-1 inhibition [6].Recently in peri-
toneal macrophages, the gastrointestinal system and
the vascular system of mPGES-1-deficient mice, a
redirection of eicosanoid metabolism was demon-
strated  [5, 7–9]. Likewise, mice lacking prostacyclin
Consequences of altered eicosanoid patterns 
for nociceptive processing in mPGES-1-deficient mice 
Christian Brenneis 
1, Ovidiu Coste 
1, Ronald Schmidt, Carlo Angioni, Laura Popp,
Rolf M. Nusing, Wiebke Becker, Klaus Scholich 
2, Gerd Geisslinger 
2 *
Pharmazentrum Frankfurt, ZAFES, Institut für Klinische Pharmakologie, Klinikum der Johann Wolfgang
Goethe-Universität Theodor-Stern-Kai 7, Frankfurt, Germany
Received: July 2, 2007; Accepted: August 24, 2007
Abstract
Cyclooxygenase-2 (COX-2)-dependent prostaglandin (PG) E2 synthesis in the spinal cord plays a major role
in the development of inflammatory hyperalgesia and allodynia. Microsomal PGE2 synthase-1 (mPGES-1)
isomerizes COX-2-derived PGH2 to PGE2. Here, we evaluated the effect of mPGES-1-deficiency on the noci-
ceptive behavior in various models of nociception that depend on PGE2 synthesis. Surprisingly, in the COX-
2-dependent zymosan-evoked hyperalgesia model, the nociceptive behavior was not reduced in mPGES-1-
deficient mice despite a marked decrease of the spinal PGE2 synthesis. Similarly, the nociceptive behavior
was unaltered in mPGES-1-deficient mice in the formalin test. Importantly, spinal cords and primary spinal
cord cells derived from mPGES-1-deficient mice showed a redirection of the PGE2 synthesis to PGD2, PGF2
and 6-keto-PGF1 (stable metabolite of PGI2).Since the latter prostaglandins serve also as mediators of noci-
ception they may compensate the loss of PGE2 synthesis in mPGES-1-deficient mice.
Keywords: pain • spinal cord • cyclooxygenase • prostaglandin • mPGES-1 • hyperalgesia
J. Cell. Mol. Med.Vol 12, No 2, 2008 pp. 639-648
1 These authors contributed equally to this work.
2 These authors contributed equally to this work.
*Correspondence to: Gerd GEISSLINGER,
pharmazentrum frankfurt, ZAFES, Klinikum der Johann
Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7,
60590 Frankfurt, Germany.
Tel: (49)-69-63 01-76 20
Fax: (49)-69-63 01-76 17
E-mail: geisslinger@em.uni-frankfurt.de
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
doi:10.1111/j.1582-4934.2007.00110.x640 © 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
synthase showed a marked increase in PGE2 and
TxA2 levels in plasma, kidney, and lung [10], suggest-
ing that the redirection of eicosanoid synthesis is not a
specific phenomenon for inhibition of mPGES-1. Most
importantly, previous studies employing prostaglandin
receptor knockout mice or using intrathecal application
of different prostaglandins demonstrated that not only
PGE2 but also PGI2, PGD2, and PGF2 induce hyper-
algesia [11–14]. Here, we investigated the effect of
mPGES-1-deficiency on the nociceptive behavior in
PGE2-dependent pain models. Surprisingly, we found
during zymosan-induced thermal hyperalgesia, an ani-
mal model that depends on COX-2-derived PGE2, that
the nociceptive behavior in mPGES-1-deficient mice
was unaltered as compared to wild-type animals. In
spinal cord cells of these knockout mice we observed a
redirection of the eicosanoid synthesis to other prono-
ciceptive prostaglandins, which might compensate the
loss of PGE2 synthesis in these knockout mice.
Material and methods
Animals
Crl:CFW(Sw) mPGES-1-deficient mice were kindly provid-
ed by Aventis (Bridgewater, USA). In these animals the
mPGES-1 expression was disturbed by the insertion of a
neomycin cassette into exon 1 of the mPGES-1 gene [15].
In all experiments the ethics guidelines for investigations in
conscious animals were obeyed and the procedures were
approved by the local Ethics Committee.In all experiments,
transgenic mice were compared with strain-, age-, and sex-
matched controls.
Peritoneal macrophages
For cell culture, all substances were purchased from Gibco
(Karlsruhe, Germany) unless otherwise specified. 0.5 ml
10% thioglycollate medium (Sigma, St. Louis, MO) was
given intraperitoneally Peritoneal macrophages were pre-
pared 4 days later as described previously [7].
Preparation of microsomal tissue fractions
Tissues were homogenized in phosphate-buffered saline
(PBS) supplemented with 0.25 M sucrose and 1 M phenyl-
methansulfonylfluoride (PMSF) (Sigma, St. Louis, MO) with
a potter and by sonification.Then the homogenate was cen-
trifuged for 10 min at 1000  g, for 15 min at 10,000  g and
for 1 hr at 170,000  g. The pellet from the last centrifuga-
tion step was re-suspended in 50 l PBS, 0.25 M sucrose
and 1 M PMSF. 30 g protein was used for western blot
analysis. COX-2, mPGES-2 and c-PGES were detected with
antibodies from Cayman (Ann Arbor, MI), mPGES-1 antibody
was from AgriSera (Vännäs, Sweden). Antibodies against
extracellular regulated kinase-1/2 (ERK-1/2) (Promega,
Madison, WI) or HSP-70 (BD Biosciences, Heidelberg,
Germany) were used to control for equal protein loading.
Spinal cord cell culture
Primary embryonic spinal cord cell cultures were prepared as
described previously [16]. Briefly, whole spinal cords were pre-
pared from mice at embryonic day 16–18 and brought into cul-
ture. Cells were then incubated for 3 days in neurobasal-medi-
um containing 10% foetal calf serum (FCS) and nerve growth
factor followed by additional 3 day incubation in serum free neu-
robasal-medium with mitosis inhibitors. Stimulation with LPS
was performed in serum free medium without mitosis inhibitors.
LC-MS/MS analysis
The following eicosanoids were monitored by LC-MS/MS:
PGF2, PGE2, PGD2, TxB2, 11-dh-TxB2, 6-keto-PGF1,

12-PGJ2, 15d-PGJ2, 13,14-dh-15-keto-PGD2, 13,14-dh-
15-keto-PGE2, PGA2, PGB2, 15d-PGD2, and LTB4.
Preparation of spinal tissue
Lumbal spinal cords were prepared and directly frozen with
liquid nitrogen. Then 200 l PBS was added and the tissue
quickly homogenized with a potter.100 l of the homogenate
were mixed with 50 l water, 20 l methanol and 20 l inter-
nal standard solution (25 ng/ml of [
2H4]-PGE2, [
2H4]-PGD2
and [
2H4]-TXB2 and 10 ng/ml of [
2H4]-PGF2 and [
2H4]-6-
keto-PGF1 in methanol) and extracted twice with 800 l
ethyl acetate.The organic phase was removed at a tempera-
ture of 45°C under a gentle stream of nitrogen.The residues
were reconstituted with 50 l of acetonitrile/water/formic acid
(20:80:0.0025, v/v, pH 4.0), and injected into the liquide chro-
matography-tandem mass spectrometry (LC-MS/MS). The
prostanoids were normalized with protein concentrations in
the sample.
Preparation of cell media
500 l cell media were mixed with 500 l 35 mM H3PO4,
20 l methanol and 20 l internal standard solution.J. Cell. Mol. Med.Vol 12, No 2, 2008
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Prostaglandins were extracted with solid-phase-extraction.
Therefore, 1 ml Nexus cartridges (Varian, Darmstadt,
Germany) were washed with 2 ml of hexane/ethylacetate/-
isopropanol (35:60:5, v/v), dried for 20 sec and conditioned
with 1 ml of methanol and 1 ml of water. 1040 l of the pre-
pared cell media (500 l cell media, 500 l 35 mM
Hv3PO4, 20 l prostaglandin standard/methanol and 20 l
internal standard solution) was loaded onto the column and
washed with 1 ml of water and 1 ml of methanol/water
(40:60, v/v). The cartridges were then dried for 7 min 
and eluted with 1 ml of hexane/ethylacetate/isopropanol
(30:65:5, v/v). The organic phase was removed at a temper-
ature of 45°C under a gentle stream of nitrogen.The residues
were reconstituted with 50 l of acetonitrile/water/formic acid
(20:80:0.0025, v/v, pH 4.0), and injected into the LC-
MS/MS. LC-MS/MS instrumentation and conditions are
described in detail in the online supplemental methods
(see Supplementary methods).
Behavioural tests
The investigator was unaware of the treatments or the
genotypes during all behavioral experiments. Acidic acid
writhing test:The writhing test was performed as described
previously [3]. Briefly, 16 l/g body weight of 0.7% acidic
acid in PBS was injected intraperitoneally. Then writhes,
defined as stretching of the torso accompanied by hyperex-
tensions of the hind limbs, were monitored over 20 min.
The formalin assay was performed as described previously
[17]. Mechanical hyperalgesia: Mice were kept in the test
cages for 4 hrs during the first day to allow accommoda-
tion. During this time each mouse was tested several times
to gain the baseline paw withdrawal thresholds. Animals
were placed on an elevated wire grid and the plantar sur-
face of the paw was stimulated using a Dynamic Plantar
Aesthesiometer (Ugo Basile, Comerio VA, Italy). The
device applies a constantly increasing force and stops on
the withdrawal of the paw, recording the corresponding
force. On day two 20 l of a Zymosan A (Sigma,
Deisenhofen, Germany) suspension (12.5 mg/ml in phos-
phate buffered saline) was injected subcutaneously into the
plantar side of left hind paw. 10 mg/kg etoricoxib was 
given i.p. 4 hrs and 6 hrs after zymosan injection. Control 
animals received dimethylsulfoxide (DMSO) alone at the 
same time points.Mechanical allodynia was assessed from
4 to 10 hrs after zymosan injection. Experiments were 
performed in air-conditioned rooms (22°C) between 8 a.m.
and 6 p.m. Right (non-injected) and left (injected) paws
were measured alternately in intervals of 5–10 min. At 
2 hrs intervals, paw withdrawal thresholds were averaged.
The measurement of paw withdrawal thresholds is report-
ed in gram with an upper limit of 5 g and the data are 
presented as mean ± SEM. For statistical evaluation, the
(injected) left paw of treated and untreated controls was
compared. Data were analyzed by Student’s t-test and
P < 0.05 was considered statistically significant.
Immunohistochemistry
Spinal (L4–5) tissues were cryostat sectioned at 10 m
and stored at 4°C until use. The staining was done as
described previously [18] with the following exceptions.
Sections were boiled in 0.1 M citric acid for 5 min with 
240 watt (microwave) and then washed twice with PBS.
Blocking was done in 3% bovine serum albumin (BSA)
(Sigma, Deisenhofen, Germany) and 10% goat serum
(Chemicon, Temecula, CA, USA) in PBS.
Multi-epitope ligand cartography (MELC) is an automat-
ed imaging technology using fluorescein isothiocyanate
(FITC)-labelled antibodies [19]. Spinal cords were removed
from BL/6 wild-type mice, cryostat-sectioned at a thickness
of 5 m and fixed in acetone at –20°C for 10 min. Before
use in the MELC system (MelTec, Magedburg, Germany)
sections were re-hydrated in PBS at 20°C, incubated with
normal goat serum for 30 min and washed again in PBS.
Slides were placed on the stage of an inverted wide-field
fluorescence microscope. Antibodies and wash solutions
were added and removed robotically.After antibody incuba-
tion for 15 min, phase contrast and fluorescence images
were acquired. Sections were then bleached using the
excitation wavelength. After acquisition of post-bleaching
images, the next cycle was started.
Primary polyclonal antibodies for PGD2-receptor (DP),
PGF2-receptor (FP) and prostacycline-receptor (IP) (1:50
dilution in PBS containing 3% BSA) were generated by immu-
nization with receptor specific peptides. The peptides used
were RNLTYVRGSVGPAT for the IP receptor, RYRSRC-
SNSTNMESSL for the DP receptor and SPAAALLSNTTC-
QTEN for the FP receptor. Immunization of rabbits was per-
formed by Eurogentec (Seraing, Belgium) according to their
standard protocol. Other antibodies used were against CGRP 
(Sigma, Deisenhofen, Germany), NF-200 (N 52) (Sigma,
Deisenhofen, Germany) and NeuN (Chemicon, Temecula,
CA, USA). As marker for lamina 2, the FITC-labelled lectin
IB-4 (Sigma, Deisenhofen, Germany) was used.
Results
Lack of mPGES-1 expression in mPGES-1 knockout
mice was confirmed by western blot analysis of 
kidney and lung tissue as well as in thioglycollate-
elicited LPS-stimulated peritoneal macrophages 
(Fig. 1A and B). As described previously, the mPGES-1
deficiency did not alter the expression levels of the642 © 2008 The Authors
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other PGE2  synthases, namely mPGES-2 and
cPGES (Fig. 1B), but caused the re-direction of the
eicosanoid synthesis to TxA2  (measured as the sta-
ble metabolite TxB2), PGI2  (measured by the stable
metabolite 6-keto-PGF1), PGF2, and PGD2
(Fig. 1C) [5, 7, 8]. Importantly, mPGES-1-deficient
mice exhibited normal motor function in the pole and
the hanging wire test (Supplementary data 1: 1A, B)
and normal basal pain thresholds in the tail flick and
hot plate tests (Supplementary data 1: 1C, D) as
compared to wild-type mice.
Then we tested the mPGES-1-deficient mice in
the writhing test, a commonly used model for viscer-
al and acute pain where unselective COX inhibitors
have a proven anti-nociceptive effect. As already
described by others [3, 5] a marked decrease in the
number of writhes in mPGES-1-deficient mice as
compared to wild-type animals was observed 
(Fig. 2A). However, in the writhing test nociceptive
transmission depends on visceral chemoreceptors
and although COX inhibitors decrease nociceptive
behavior in this pain model the mode of action of
PGE2 in this nociceptive response is still unclear [20].
In contrast, in the formalin test, a pain model that
depends on the generation of PGE2 in the spinal
cord, the mPGES-1-deficient mice showed only a
slight, non-significant decrease in their nociceptive
behavior as compared to wild-type mice (Fig. 2B)
although the PGE2 concentrations in the spinal cord
were significantly decreased (Fig. 2C).
To characterize the effect of mPGES-1-deficiency
in a model of inflammatory hyperalgesia that is
known to depend on COX-2-mediated PGE2 synthe-
sis, we determined the nociceptive behavior of
mPGES-1-deficient mice in zymosan-evoked
mechanical hyperalgesia. Zymosan injection into the
left hind paw of wild-type animals resulted in a 
reduction of the mechanical threshold over 10 hrs.
As expected administration of the selective COX-2
inhibitor etoricoxib (positive control) caused a
marked decrease in the nociceptive behavior (antihy-
peralgesia) of these animals reaching significance
after 10 hrs (Fig. 3A). However, surprisingly the
reduction of the mechanical threshold following
zymosan injection was similar in wild-type and
mPGES-1-deficient mice (Fig. 3B). In order to study
the prostanoid synthetic pathways regarding a possi-
ble redirection of the prostanoid synthesis that may
lead to a functional compensation of the loss of
PGE2, we determined the concentrations of various
eicosanoids in extracts from L4–L5 segments from
spinal cords of zymosan-treated mice. As compared
Fig. 1 mPGES-1 expression and re-direction of eicosanoid metabolism in mPGES-1-deficient peritoneal macrophages.
(A) Microsomal fractions (see Supplementary methods for details) of kidney and lung tissues from wild-type and mPGES-
1-deficient mice were subjected to western blot analysis to detect relative protein amounts.(B) Peritoneal macrophages
were stimulated with 5 g/ml LPS for 15 hrs and then subjected to western blot analysis to detect relative protein
amounts (see Supplementary methods for details). (C) Peritoneal macrophages were stimulated with 5 g/ml LPS 
for 15 hrs and prostaglandin levels determined from medium by LC-MS/MS. Data are shown as percent of all
prostaglandins and are expressed as the mean ± S.E.M. (n =9 ) .* P < 0.05.J. Cell. Mol. Med.Vol 12, No 2, 2008
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to wild-type mice the PGE2 levels were significantly
lower in the mPGES-1-deficient mice (Fig.3C).Since
the difference in the total amount of PGE2 between
both animal groups was relative small, it was not sur-
prising that despite a tendency towards an increased
synthesis of other prostaglandins (i.e. PGD2), it only
reach significance for two eicosanoids, TxB2 and
PGF2 (Fig. 3C). Most importantly, studies employing
knockout mice or using intrathecal administration of
different prostaglandins demonstrated that not only
PGE2 but also PGI2, PGD2, and PGF2 induce hyper-
algesia or sensitize nociceptive neurons [11–14].
Next, we employed primary cultures from embry-
onic spinal cords to study the effect of mPGES-1
deficiency on the prostanoid synthesis in more detail.
LPS-stimulation of primary spinal cord neurons
resulted in an up-regulation of the COX-2 expression
in mPGES-1 as well as wild-type animals (Fig. 4A),
while mPGES-1 was, as expected, only induced in
cultures from wild-type mice. The expression of
cPGES and mPGES-2 protein was unaltered, demon-
strating that, like in LPS-stimulated macrophages
(Fig. 1B), a compensatory up-regulation does 
not occur. In the spinal cord cultures only PGE2,
PGD2, 6-keto-PGF1, PGF2, and TxB2 were 
produced at concentrations above the detection level
of the LC-MS/MS-system used. Notably, the synthe-
sis of 6-keto-PGF1 and PGF2 was already higher 
in unstimulated mPGES-1-deficient cells as com-
pared to wild-type cells (Fig. 4B). After LPS-stimula-
tion a 10-fold increase in the PGE2 synthesis
occurred in wild-type cells (Fig. 4C). Cells from
mPGES-1-deficient mice produced only 20% of the
PGE2 levels seen in wild-type cells while the synthe-
sis of 6-keto-PGF1, PGF2 and PGD2 was signifi-
cantly increased. A different pattern of an altered
eicosanoid synthesis was seen in cells that were
stimulated with TNF instead of LPS (Supplementary
data 2). This finding indicates that the shift in the
prostaglandin synthesis depends on the stimulus
used and is probably due to differences in the
induced expression of the terminal, synthases.
Finally, in accordance with this observation the non-
specific mPGES-1 inhibitor MK-886 inhibited the
PGE2 production in wild-type spinal cord cultures,
while the 6-keto-PGF1 synthesis increased in an
inverse manner (Fig. 4D). These data indicate that
mPGES-1-inhibition either through genetic deletion
or pharmacological inhibition induces a similar redi-
rection of the eicosanoid synthesis.
To investigate whether or not the prostaglandins,
which are compensatorily synthesized in absence of
mPGES-1, might be involved in nociceptive processing
in the outer laminae of the dorsal horn, we analysed
Fig. 2 Nociceptive behavior of mPGES-1-deficient mice in the writhing and the formalin assay. (A) Responses in the
acetic acid writhing assay. Total number of responses during 20 min after acid administration is shown as the
mean ± S.E.M.(n = 7–9).One-tailed Student’s t-test: * P < 0.05.(B) Formalin assay with mPGES-1
–/– and wild-type ani-
mals. Licking time between indicated time periods was measured. Data shown are the mean ± S.E.M. (n = 9). (C) PGE2
was extracted from spinal cord segments L4–L5 1 hr after formalin injection. Data are shown as the mean 
± S.E.M. (n = 6–7).644 © 2008 The Authors
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the expression pattern of their corresponding recep-
tors. Immunohistochemical staining of spinal cord
sections showed that FP is expressed in neuronal
and non-neuronal cells in the outer laminae of the
dorsal horn (Fig. 5A). A similar expression pattern
was observed for the DP and IP (Fig. 5B), which also
co-localize in part with NeuN-immunostaining through-
out the dorsal horn in spinal cords of adult mice.
Discussion
Here we show that mPGES-1-deficient mice, although
the induced spinal PGE2 synthesis is significantly
decreased, do not exhibit a reduced nociceptive
behaviour in PGE2-dependent inflammatory pain
models. Previously it has been demonstrated for sev-
eral systems, such as peritoneal macrophages, the
gastrointestinal system and the vascular system that
in mPGES-1-deficient mice a redirection of eicosanoid
metabolism occurs [5, 7–9]. We found that also in the
spinal cord and in primary spinal cord cells, a redirec-
tion of the eicosanoid synthesis from PGE2 to 
other prostaglandins with pro-nociceptive properties
(PGD2, PGF2 and prostacyclin) occurs. For these
prostaglandins, it has been described that intrathecal
injection of PGD2 [14], PGI2 [21] or PGF2 [11, 13]
induce allodynia or hyperalgesia [22] and it has been
speculated that PGD2 might even mediate PGE2-
evoked pain states, since PGDS-deficient mice 
do not develop PGE2-induced allodynia, [14, 23].
Furthermore, IP receptor-deficient mice as well as ani-
mals that received IP receptor antagonists exhibit a
significantly reduced nociceptive behavior [12, 24–26].
Taken together, these findings suggest that the
redirection of the pro-staglandin synthesis in the
spinal cord interferes with the anti-nociceptive effect
of the decreased PGE2 synthesis. Since the PGE2
synthesis produces its pro-nociceptive actions mainly
in neurons of lamina I and II in the dorsal horn, the
expression of the receptors for PGD2, PGF2 and
PGI2 in this region supports a possible compensation
of the decreased PGE2 synthesis by one or more of
these prostaglandins. Notably, the mechanisms by
which FP, IP and DP receptors increase spinal noci-
ceptive processing may be different from the PGE2
pathway. For example, it was recently shown that the
re-direction of the prostaglandin synthesis in
absence of mPGES-1 promotes iNOS expression
Fig. 3 Nociceptive behavior of mPGES-1-deficient mice
in zymosan-induced hyperalgesia. (A) Effect of etoricoxib
on zymosan-evoked mechanical hyperalgesia. Zymosan
was injected at time zero. Etoricoxib was given 4 and 6
hrs later (arrows). Data shown are the mean ± S.E.M.
(n = 8–9). One-tailed Student’s t-test: *P<0.05. (B) Same
as panel A except wild-type and mPGES-1
–/– mice were
tested. Data are shown as the mean ± S.E.M. (n = 11).
(C) PGE2 was extracted from spinal cord segments
L4–L5 10 hrs after zymosan injection.Data are presented
as mean ± S.E.M. (n = 3–8). Student’s t-test: *P < 0.02,
**P < 0.01.J. Cell. Mol. Med.Vol 12, No 2, 2008
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and nitric oxide synthesis in embryonic fibroblasts
[27].Thus, the ‘re-directed’ prostanoids may increase
spinal nociceptive processing through nitric oxide or
other pro-nociceptive signaling elements.
Finally, and at a first view confusing, mPGES-1-
deficient mice had fewer signs of inflammation in ani-
mal models of rheumatoid arthritis [3, 5]. These 
data suggest that in these models, the re-direction of
Fig. 4 Eicosanoid re-direction in mPGES-1-deficient primary spinal cord cultures. (A) Primary spinal cord cultures were
stimulated with 5 g/ml LPS for 15 hrs and then subjected to western blot analysis. (B–C) Spinal cord cultures were
incubated in serum-free medium for 15 hrs in absence (B) or presence (C) of 5 g/ml LPS.Data are shown as the mean
± S.E.M.(n = 5, panel B;n = 14, panel C).Two-tailed Student’s t-test:*P < 0.05, **P < 0.01.(D) Spinal cord cultures from
wild-type mice were incubated with 5 g/ml LPS and the indicated MK-886 concentrations for 15 hrs. Data are shown
as percent of control and are the mean ± S.E.M. (n = 3). Student’s t-test: *P < 0.05.646 © 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 5 Prostaglandin receptors DP, FP and IP are expressed in dorsal horn neurons. (A) Immunohistochemical analy-
sis of a L4–L5 spinal cord section from wild-type mice using the MELC technology. Signals are shown in false colors.
CGRP (blue) was used as marker for lamina 1 (LI) and IB4 (pink) as marker for lamina 2 (LII). Arrows indicate FP-
expressing neurons (white), or FP-expressing non-neuronal cells (yellow). (B) Immunohistochemical analysis of PGD2
(DP) and prostacyclin (IP) receptors in the spinal cord.Sections are from spinal cords (L4–5) of zymosan-treated (8 hrs)
wild-type mice. DAPI was used for nuclear staining (blue), NeuN to stain neurons (red) and specific antibodies for the
indicated prostaglandin receptors (green).The ipsilateral dorsal horn is shown.J. Cell. Mol. Med.Vol 12, No 2, 2008
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eicosanoid synthesis does not result in the synthesis
of prostanoids that can fully compensate for the loss
of PGE2 production.Since some prostanoids such as
PGI2 and PGF2, have anti-inflammatory effects and
others, such as TXA2 and PGD2, exhibit pro- or anti-
inflammatory properties depending on the specific
inflammatory setting [28], it can be speculated that in
mPGES-1-deficient mice the redirected prostanoid
synthesis may even help to enhance the desired anti-
inflammatory effect. Indeed, recently it was shown
that  in mPGES-1-deficient mice the re-direction of
eicosanoid synthesis from PGE2 to PGI2 decreases
the number of lesional macrophages and foam cells
in atheriosclerotic plaques, thereby limiting atherio-
genesis [29]. Whether or not mPGES-1 inhibitors
may qualify as useful anti-inflammatory drugs needs
further research. Additionally, results obtained in the
writhing assay suggest some potency in the treat-
ment of visceral pain. However, an anti-nociceptive
effect of a reduced PGE2 production by inhibition of
mPGES-1 seems to be compensated by the re-direc-
tion of the eicosanoid synthesis towards other prono-
ciceptive prostaglandins, since not only PGE2 but
also most other prostaglandins result in peripheral
and central sensitization in the nociceptive system
[23]. However, due to the variability in the eicosanoid
redirection patterns that even differ between the var-
ious mice strains [6], the effect of mPGES-1 inhibition
on human pain perception can only be evaluated
after the appropriate studies in humans employing
selective mPGES-1-inhibitors have been performed.
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